{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:59:13Z","timestamp":1781657953119,"version":"3.54.5"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s13555-025-01548-2","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T18:09:29Z","timestamp":1758910169000},"page":"3593-3604","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Aquagenic Pruritus Questionnaire: Predicting Myeloproliferative Neoplasms in Patients with Aquagenic Pruritus"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4305-0713","authenticated-orcid":false,"given":"Felix","family":"Witte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Weisshaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Metz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Koschmieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Isfort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas E.","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Griesshammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svenja","family":"Royeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"St\u00e4nder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Zeidler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"1548_CR1","first-page":"1385","volume":"212","author":"W Shelley","year":"1970","unstructured":"Shelley W. Post-wetness (aquagenic) pruritus. JAMA. 1970;212:1385.","journal-title":"JAMA"},{"issue":"1","key":"1548_CR2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0190-9622(85)70149-1","volume":"13","author":"HK Steinman","year":"1985","unstructured":"Steinman HK, Greaves MW. Aquagenic pruritus. J Am Acad Dermatol. 1985;13(1):91\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1548_CR3","doi-asserted-by":"publisher","first-page":"496","DOI":"10.2340\/00015555-2906","volume":"98","author":"E Lelonek","year":"2018","unstructured":"Lelonek E, Matusiak \u0141, Wr\u00f3bel T, Szepietowski JC. Aquagenic pruritus in polycythemia vera: clinical characteristics. Acta Derm Venereol. 2018;98(5):496\u2013500.","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"1548_CR4","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1111\/jdv.18990","volume":"37","author":"C Le Gall-Ianotto","year":"2023","unstructured":"Le Gall-Ianotto C, Ficheux AS, Lippert E, et al. Differences between aquagenic and non-aquagenic pruritus in myeloproliferative neoplasms: an observational study of 500 patients. J Eur Acad Dermatol Venereol. 2023;37(6):1175\u201383.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"1548_CR5","first-page":"499","volume":"26","author":"I Potasman","year":"1990","unstructured":"Potasman I, Heinrich I, Bassan HM. Aquagenic pruritus: prevalence and clinical characteristics. Isr J Med Sci. 1990;26(9):499\u2013503.","journal-title":"Isr J Med Sci"},{"key":"1548_CR6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1471-5945-9-4","volume":"9","author":"TA Salami","year":"2009","unstructured":"Salami TA, Samuel SO, Eze KC, Irekpita E, Oziegbe E, Momoh MO. Prevalence and characteristics of aquagenic pruritus in a young African population. BMC Dermatol. 2009;9:4.","journal-title":"BMC Dermatol"},{"key":"1548_CR7","doi-asserted-by":"publisher","first-page":"8420123","DOI":"10.1155\/2020\/8420123","volume":"2020","author":"JN Teclessou","year":"2020","unstructured":"Teclessou JN, Kombate K, Akakpo AS, et al. Prevalence and clinical characteristics of aquagenic pruritus among medical and pharmacy students in Lom\u00e9 (Togo). Dermatol Res Pract. 2020;2020:8420123.","journal-title":"Dermatol Res Pract"},{"issue":"8","key":"1548_CR8","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/ajh.23474","volume":"88","author":"FP Siegel","year":"2013","unstructured":"Siegel FP, Tauscher J, Petrides PE. Aquagenic pruritus in polycythemia vera: characteristics and influence on quality of life in 441 patients. Am J Hematol. 2013;88(8):665\u20139.","journal-title":"Am J Hematol"},{"issue":"1","key":"1548_CR9","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jaad.2017.10.021","volume":"85","author":"E Lelonek","year":"2021","unstructured":"Lelonek E, Matusiak \u0141, Wr\u00f3bel T, Szepietowski JC. Aquagenic pruritus in polycythemia vera: a cross-sectional study. J Am Acad Dermatol. 2021;85(1):211\u20133.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1548_CR10","doi-asserted-by":"publisher","first-page":"266","DOI":"10.2340\/00015555-1949","volume":"95","author":"S St\u00e4nder","year":"2015","unstructured":"St\u00e4nder S, Pogatzki-Zahn E, Stumpf A, et al. Facing the challenges of chronic pruritus: a report from a multi-disciplinary medical itch centre in Germany. Acta Derm Venereol. 2015;95(3):266\u201371.","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"1548_CR11","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology life quality index (DLQI)\u2013a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210\u20136.","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"1548_CR12","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/jdv.15225","volume":"33","author":"C Zeidler","year":"2019","unstructured":"Zeidler C, Steinke S, Riepe C, et al. Cross-European validation of the ItchyQoL in pruritic dermatoses. J Eur Acad Dermatol Venereol. 2019;33(2):391\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1548_CR13","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/jdv.17111","volume":"35","author":"M Storck","year":"2021","unstructured":"Storck M, Sandmann S, Bruland P, et al. Pruritus intensity scales across Europe: a prospective validation study. J Eur Acad Dermatol Venereol. 2021;35(5):1176\u201385.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1548_CR14","doi-asserted-by":"publisher","first-page":"230","DOI":"10.2340\/00015555-2494","volume":"97","author":"S St\u00e4nder","year":"2017","unstructured":"St\u00e4nder S, Blome C, Anastasiadou Z, et al. Dynamic pruritus score: evaluation of the validity and reliability of a new instrument to assess the course of pruritus. Acta Derm Venereol. 2017;97(2):230\u20134.","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"1548_CR15","first-page":"e317","volume":"38","author":"G Biazus Soares","year":"2024","unstructured":"Biazus Soares G, Vailoces V, Choragudi S, Yosipovitch G. Aquagenic pruritus: a web-based survey study exploring itch characteristics, therapeutic options and patient perspectives. J Eur Acad Dermatol Venereol. 2024;38(4):e317\u20139.","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01548-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01548-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01548-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T09:21:59Z","timestamp":1763198519000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01548-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":15,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1548"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01548-2","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"11 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Felix Witte: declares no conflicts of interest. Elke Weisshaar: has received speaker honoraria\/consulting fees from Sanofi, Menlo, TREVI and Galderma. Martin Metz: is an investigator for Almirall, Celldex, Escient, Galderma, Incyte, Lilly, Pfizer, Regeneron, Sanofi, Teva and has received speaker honoraria\/travel fees from Almirall, AbbVie, Celldex, Escient, Incyte, Galderma, Pfizer, Regeneron, Sanofi, Teva and Vifor. Steffen Koschmieder: is an investigator for Pfizer, Incyte \/ Ariad, Novartis, AOP Pharma, BMS, Celgene, Geron, Janssen, CTI, Roche, Baxalta, Sanofi, MPN Hub, Sierra Oncology, GlaxoSmith Kline, AbbVie, PharmaEssentia and has received speaker honoraria\/travel fees from Alexion, Novartis, BMS, Celgene, Incyte \/ Ariad, AOP Pharma, CTI, Pfizer, Sanofi, Janssen, Geron, Imago Biosciences, GSK, PharmaEssentia, Sierra Oncology, AbbVie, iOMEDICO, Shire, Roche, AOP Pharma, Karthos, Abbvie, Baxalta, Sierra Oncology, Imago Biosciences. Susanne Isfort: is an investigator for Pfizer, Incyte, GSK, Silence Therapeutics, Novartis and has received speaker honoraria\/travel fees from AOP Orphan, Alexion, Janssen, Novartis, Pfizer, Mundipharma, Roche, Hexal, AbbVie, BMS, Incyte, GSK, Silence Therapeutics. Andreas E. Kremer: is an investigator and\/or speaker and\/or advisor for Abbvie, Advanz, Alentis, AlphaSigma, Astellas, AstraZeneca, Attovia Therapeutics, Avior, Bayer, BMS, B\u00f6hringer Ingelheim, CymaBay, Dr. Falk, Gilead, GSK, Guidepoint, Intercept, Ipsen, Mirum, MSD, Novo Nordisk, Rectify Pharma, Roche, Takeda, PBC Foundation, Swiss Association for the Study of the Liver (SASL), Swiss Hepa and has received speaker honoraria\/travel fees from Abbvie, Advanz, Alentis, AlphaSigma, Astellas, AOP Orphan, AstraZeneca, Attovia Therapeutics, Avior, Bayer, BMS, B\u00f6hringer Ingelheim, CymaBay, Falk Foundation, Gilead, GSK, Guidepoint, Intercept, Ipsen, Johnson&Johnson, Medscape, Mirum, MSD, Newbridge, Novartis, Novo Nordisk, Rectify Pharma, Roche, Takeda, Vertex Viofor. Martin Griesshammer: has received speaker honoraria\/travel fees from AOP Orphan, Novartis, BMS, AbbVie, Pfizer, Roche, Janssen, Gilead, AstraZeneca, Sierra, Lilly, GSK. Svenja Royeck: was advisor, speaker or investigator for Incyte Inc., Eli Lilly, LEO Pharma and Sanofi\/Regeneron. Sonja St\u00e4nder: was speaker and\/or consultant and\/or investigator and\/or has received research funding from Almirall S. A., Amgen Inc., Amgen Europe GmbH, Celldex Therapeutics Inc., Clexio Biosiences Ltd., Focus-Insight Healthtech Group Co. Ltd., Galderma Laboratorium GmbH, Galderma R&D LLC., Galderma S.A., GSK R&D Ltd., Incyte Corporation, Klirna Biotech Inc., Leo Pharma, Lilly Deutschland GmbH, Novartis Pharma GmbH, Sanofi-Aventis Deutschland GmbH, Sanofi-Aventis R&D, Sanofi Genzyme Corporation, TouchIME, Vifor Pharma Deutschland GmbH P. G. Unna Academy. Claudia Zeidler: is an investigator for Amgen, Novartis, Janssen, Pfizer, UCB, Lilly, Abbvie, Boehringer Ingelheim, Sanofi, Regeneron, Leo, Galderma and has received speaker honoraria\/travel fees from Dermasence, Beiersdorf, Leo, Sanofi, Novartis, Unna Akademie, Allmiral and AbbVie.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was reviewed and approved by \u00c4rztekammer Westfalen Lippe and the Medical Faculty of the University of M\u00fcnster (2014-162-f-S) and from each participating center (hematology centers at the universities of Erlangen, Aachen, and Minden; dermatology centers at the universities of M\u00fcnster, Berlin, and Heidelberg) and was registered in the German Clinical Trials Registry (DRKS 00006075). The patients in this manuscript have given written informed consent to the participation in this study. This study was performed according to the principles laid down in the Declaration of Helsinki and following the Guidelines of Good Clinical Practice.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}